title: Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
abstract: The long prevailing hypothesis of schizophrenia pathogenesis implicates dopaminergic systems in the mesolimbic pathways as responsible for the positive symptoms of schizophrenia (hallucinations and delusions) and those in the mesocortical pathway as contributing to the negative symptoms (e.g., social disconnection, flattened affect and anhedonia). Several challenges to the dopamine hypothesis and the proposal of an alternative hypothesis implicating glutamate have provided additional support for the development of non-dopaminergic drugs for the management of schizophrenia symptomatology. Furthermore, preclinical and clinical evidence of alpha7 neuronal nicotinic acetylcholine receptor-mediated benefits in the triad of positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia, as well as the genetic linkage of this receptor to the disease, have added another level of complexity. Thus schizophrenia is increasingly believed to involve multi-neurotransmitter deficits, all of which may contribute to altered dopaminergic tone in the mesolimbic, mesocortical and other areas of the brain. In this paper we provide a model that reconciles the dopamine, glutamate and alpha7 cholinergic etiopathogenesis and is consistent with the clinical benefit derived from therapies targeted to these individual pathways.
authors.affiliation: Preclinical Research, Targacept, Inc., Winston-Salem, NC 27101-4165, USA. merouane.bencherif@targacept.com
authors.forename: Merouane
authors.initials: M
authors.lastname: Bencherif
authors.forename: Michal K
authors.initials: MK
authors.lastname: Stachowiak
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Kucinski
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Lippiello
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018679:Cholinergic Agonists / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D018698:Glutamic Acid / Q000502:physiology; D006801:Humans; D008959:Models, Neurological; D011978:Receptors, Nicotinic / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D064569:alpha7 Nicotinic Acetylcholine Receptor; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D018679:Cholinergic Agonists; C579167:Chrna7 protein, human; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D004298:Dopamine